Not for distribution to U.S. newswire services or for dissemination in the United States. CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Northview Residential REIT (the “REIT”) today announced its May 2025 cash distribution amounts on its outstanding Class A Units, Class C Units and Class F Units (collectively, the “Units”) in the amount of C$0.091146 per Unit (C$1.09 per Unit on an annualized basis). The distribution will be payable on June 16, 2025 to holders of Units of record at May 31, 2025. About ...

Core Points - THOR Industries, Inc. will release its fiscal 2025 third quarter earnings on June 4, 2025, before the market opens [1] - The earnings release will be accompanied by a comprehensive Q&A document and a slide presentation available on the company's website [2] - THOR Industries is the largest manufacturer of recreational vehicles globally, owning multiple operating subsidiaries [3] Company Information - THOR Industries, Inc. is recognized as the sole owner of subsidiaries that collectively represent the world's largest manufacturer of recreational vehicles [3]

Core Viewpoint - Bicara Therapeutics Inc. announced updated interim data from its Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for patients with recurrent/metastatic head and neck squamous cell carcinoma, highlighting promising efficacy and safety results [1][2][4]. Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with ficerafusp alfa as its lead program [10]. - Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration by targeting both epidermal growth factor receptor (EGFR) and human transforming growth factor beta (TGF-β) [8][10]. Clinical Trial Details - The Phase 1/1b trial evaluated ficerafusp alfa in patients with first line recurrent/metastatic head and neck squamous cell carcinoma, specifically those with a PD-L1 combined positive score (CPS) of ≥1 [4]. - Updated interim data showed a 64% objective response rate in the HPV-negative population, with 21% achieving a complete response [4]. - Median progression-free survival was reported at 9.8 months, and the 12-month overall survival rate was 61% [4]. Presentation and Data Sharing - Bicara Therapeutics will present the full dataset during an oral presentation at the 2025 ASCO Annual Meeting, scheduled for June 1, 2025 [1][3][4]. - The conference call will provide further insights into the overall survival and duration of response data following the ASCO presentation [1][5]. Industry Context - Head and neck squamous cell carcinoma (HNSCC) is a common malignancy with a rising incidence, expected to reach one million new cases globally by 2030 [6]. - Approximately 80% of patients with recurrent/metastatic HNSCC are HPV-negative, which is associated with worse survival outcomes and a critical unmet need for effective therapies [7].

Menlo Park, CA, May 22, 2025 (GLOBE NEWSWIRE) -- Cal Redwood Acquisition Corp. (the “Company”) announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit on May 22, 2025. The units are expected to be listed for trading on the Nasdaq Global Market under the ticker symbol “CRAQU” beginning May 23, 2025. Each unit consists of one Class A ordinary share and one right to receive one tenth of a Class A ordinary share upon the consummation of an initial business combina ...

- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of ...

The Organizing Committee of Sanmenxia Yellow River Cultural Tourism FestivalSANMENXIA, China, May 22, 2025 (GLOBE NEWSWIRE) -- On May 20th, the ceremony of Laozi Digital Human Launch and Online Promotion, named "Dialogue Across Time and Space", took place at the Hangu Pass Historical and Cultural Tourism Zone, renowned as the "Millennia-Old Strategic Pass and Birthplace of Taoism". This marks China's first digital human of Laozi, integrating cutting-edge technologies such as AI, 3D modeling and natural sema ...

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Medallion Bank (Nasdaq: MBNKP, MBNKO), an FDIC-insured bank providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners, announced today that it has closed a public offering of 3,100,000 shares of its Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series G, par value $1.00 per share, with a liquidation amount of $25 per share (the “Series G Preferred ...

WEST DES MOINES, Iowa, May 22, 2025 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) announced that it has declared the following preferred stock dividends on its non-cumulative preferred stock (represented by depositary shares, each representing a 1/1,000th interest in a share of preferred stock), payable on June 30, 2025 to holders of record as of June 15, 2025. Quarterly dividend of $396.875 per share on the company’s 6.35% Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock, Series A (the ...

May 22, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four res ...

ALEXANDRIA, La., May 22, 2025 (GLOBE NEWSWIRE) -- Red River Bancshares, Inc. (Nasdaq: RRBI) (the “Company”) announced today that, on May 22, 2025, the Company entered into a stock repurchase agreement with a shareholder for the repurchase by the Company of 100,000 shares of its common stock in a privately-negotiated transaction for a purchase price of $5.1 million. The purchase price reflects a discount to the 10-, 20-, and 30-day volume weighted average price on May 20, 2025. Blake Chatelain, the Company’s ...